Back

Anticoagulation versus antiplatelet therapy in patients with embolic stroke of unknown source: A systematic review and meta-analysis

30 March 2025 (16:30 - 17:15)
Organised by: Logo
Congress Presentation Part of: Stroke prevention Oral Anticoagulation EHRA Premium Access EHRA 2025 European Heart Rhythm Association (EHRA)

About the speaker

Photo
Doctor Irum Kotadia

King's College London, London (United Kingdom of Great Britain & Northern Ireland)

6 More presentations in this session

Presentation thumbnail
Boosting anticoagulation adherence in atrial fibrillation and atrial flutter: the impact of a simple nudge strategy before elective electrical cardioversion
Doctor P. Mangas Palma (Porto, PT)
Abstract Slides Video
Presentation thumbnail
In-hospital outcomes of left atrial appendage (LAA) occlusion among cancer patients with atrial fibrillation: a nationwide US study
Associate Professor E. Leshem (Hadera, IL)
Abstract Slides Video
Presentation thumbnail
Alcohol use disorder and initiation of oral anticoagulant therapy in patients with atrial fibrillation: a nationwide cohort study
Mr M. Vanhanen (Turku, FI)
Abstract Slides Video
Presentation thumbnail
Extraction of Watchman device using a double transeptal approach
Doctor V. La Fazia (Austin, US)
Abstract Slides Video
Presentation thumbnail
What is the stroke risk threshold for anticoagulation to provide net benefit in atrial fibrillation? A Markov decision model analysis
Doctor K. Teppo (Turku, FI)
Abstract Slides Video

Access the full session

Session thumbnail
Stroke prevention

The Event

Event poster

EHRA 2025

30 March 2025 16:30 CET
You may be interested in
thumbnail
Congress Presentation
Oral anticoagulants or antiplatelets for cryptogenic stroke: a systematic review and meta-analysis
thumbnail
Congress Presentation
Efficacy of anticoagulation in atrial fibrillation: evidence from 36 years of randomized controlled trials - a meta-analysis
thumbnail
Congress Presentation
Extracranial systemic embolic events in patients with atrial fibrillation: an individual patient-level meta-analysis of 71 683 patients randomized to NOAC vs warfarin from the COMBINE-AF study

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources